

AN INTERVENTIONAL PHASE III ACCELERATED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF RECEPTOL® ORAL SPRAY (RADHA 108 NANO PEPTIDES) USED IN HIV POSITIVE PATIENTS WITH MULTIPLE SYMPTOMS AS A STAND-ALONE MONO THERAPY AND THAT COULD BE AN ANSWER TO ALZHEIMER'S AND DEMENTIA AND OTHER IMMUNITY DISORDERS

Pawan Saharan

Biomix Network Inc., USA and India

Receptol® oral spray was used in HIV positive patients as a model with CD4 counts of more than 100 cells/cmm and CD8 count of more than 400 cells/cmm to determine its immunity boosting capacity based on large number of indications approved by US and EU PTO (US Patent# 9,249,188) in 2016 including for Alzheimer's and Dementia. Receptol® oral spray is assessed for its efficacy in treatment of HIV in a study without anti-retroviral therapy/observed therapy-short course (ART) based on the reduction in viral load and clinical symptoms as primary efficacy results. Absolute CD4/CD8 counts and various physical parameters were evaluated as secondary efficacy results. Receptol active ingredient is Patented Radha108 nano peptides, isolated from mammalian colostrum with vaccine like antiviral and immunomodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors. The mode of action is based on Radha 108 crossing the blood brain barrier and sending signals via pituitary to thymus and bone marrow to build body's own immune system naturally strong via release of cytokines, interleukins and interferon etc. creating paradigm shift in healthcare from prevention to cure which was exhibited in this study. It cures all clinical and physical symptoms associated with AIDS and reduction in viral load and increase in CD4 absolute count with in a period of 3 months accelerated study conducted by Indian Council of Medical Research, Govt of India. Similar effects were observed in observational study conducted on Alzheimer's and dementia and other immunity disorders.

drpawan@biomix.in
info@biomix.in